Apitegromab (SRK-015) Australia: What Does the Research Show?
Apitegromab is an experimental monoclonal antibody developed by Scholar Rock that selectively prevents the activation of myostatin. Unlike several earlier approaches, it is designed to target inactive forms of myostatin before they become active.
Last updated: August 2026Apitegromab is one of the most advanced drugs in the emerging field of myostatin inhibition.
Developed by Scholar Rock and originally known as SRK-015, apitegromab is designed to prevent myostatin from becoming biologically active.
Myostatin is a naturally occurring protein that helps regulate how much skeletal muscle the body maintains.
Blocking this pathway has produced dramatic muscle growth in some animal models, which has made myostatin one of the most closely watched targets in muscle biology.
Apitegromab takes a more selective approach than many earlier experimental drugs.
Rather than broadly blocking receptors used by multiple growth factors, it targets the inactive precursor forms of myostatin itself.
Apitegromab attempts to stop myostatin before it becomes active, reducing one of the body’s natural signals that restricts skeletal muscle.
What is apitegromab?
Apitegromab is an investigational fully human monoclonal antibody developed by Scholar Rock.
Its purpose is to selectively inhibit the activation of myostatin, also known as GDF-8.
Myostatin is primarily associated with skeletal muscle and acts as a natural negative regulator of muscle growth.
In other words, myostatin helps place a biological limit on how much skeletal muscle the body builds and maintains.
Apitegromab attempts to reduce that signal without broadly blocking the entire activin receptor system.
Apitegromab is a genuine myostatin inhibitor, but its mechanism is unusual. It targets the precursor forms of myostatin before the protein becomes active.
What is SRK-015?
SRK-015 was the development code used for apitegromab.
Older research papers and clinical trial records may therefore refer to the compound as SRK-015 rather than apitegromab.
The following names refer to the same investigational drug:
- Apitegromab
- SRK-015
- Anti-proMyostatin antibody SRK-015
It is a fully human IgG4 monoclonal antibody.
How does apitegromab work?
To understand apitegromab, it helps to understand that myostatin does not begin its life in the body as an active protein.
Myostatin is initially produced as an inactive precursor.
It progresses through different forms before mature myostatin is released and becomes capable of activating receptors that restrict muscle growth.
myostatin
myostatin
myostatin
reduced
Apitegromab binds the pro and latent forms of myostatin with high affinity.
This prevents the final activation step and therefore reduces the amount of active myostatin available to signal through muscle cells.
Why is apitegromab different from other myostatin inhibitors?
Selectivity is one of the most important features of apitegromab.
Myostatin belongs to the larger TGF-beta family of growth factors.
Several related proteins use overlapping receptors and signalling pathways.
Some older experimental approaches attempted to increase muscle by broadly blocking activin type II receptors.
This can produce a powerful effect, but it may also interfere with other proteins that use the same receptors.
Apitegromab takes a different approach.
Can interfere with signalling from myostatin as well as several related proteins.
Selectively binds pro and latent myostatin before mature myostatin becomes active.
The goal is to obtain the muscle benefits of reducing myostatin while avoiding unnecessary interference with related signalling pathways elsewhere in the body.
Is apitegromab a peptide?
No.
Like trevogrumab and garetosmab, apitegromab is a monoclonal antibody.
It is therefore considerably larger and more complex than the synthetic research peptides commonly discussed online.
The drug used in clinical trials is manufactured as a pharmaceutical biologic and has been administered by intravenous infusion.
Products marketed online as “myostatin peptides” should not be assumed to contain apitegromab or to be equivalent to the pharmaceutical material used in Scholar Rock’s clinical trials.
Does apitegromab build muscle?
Apitegromab is designed to increase the body’s capacity to maintain skeletal muscle by reducing myostatin activity.
However, there is an important difference between its biological mechanism and the claims sometimes made about myostatin inhibitors online.
The strongest clinical evidence for apitegromab comes from people with spinal muscular atrophy.
These trials were designed to measure improvements in motor function, not bodybuilding or muscle gain in healthy adults.
There is currently no Phase 3 evidence showing that apitegromab causes dramatic muscle growth in healthy people who do not exercise.
Apitegromab has demonstrated clinically meaningful improvements in motor function in people with SMA. That is strong evidence that targeting muscle through myostatin inhibition can produce functional benefits, but it is not evidence of extreme muscle growth in healthy adults.
Why is apitegromab being developed for spinal muscular atrophy?
Spinal muscular atrophy, or SMA, is a genetic neuromuscular disease that causes progressive muscle weakness and loss of motor function.
Modern SMA treatments can target the underlying SMN biology responsible for the disease.
Examples include nusinersen and risdiplam.
Apitegromab takes a different approach.
Rather than targeting the genetic cause of SMA, it directly targets the muscle side of the disease.
medicine
muscle targeting
motor function
Scholar Rock is therefore developing apitegromab as an additional treatment used alongside established SMN-targeted medicines.
The Phase 3 SAPPHIRE trial
The most important clinical study of apitegromab to date is the SAPPHIRE Phase 3 trial.
SAPPHIRE was a randomized, double blind and placebo controlled study involving people with later onset Type 2 or Type 3 SMA.
Participants were already receiving an approved SMN-targeted treatment such as nusinersen or risdiplam.
Apitegromab or placebo was then added to their existing therapy.
SAPPHIRE represents a much later stage of development than most experimental myostatin drugs.
ClinicalTrials.gov reports actual enrolment of 188 participants.
Motor function was evaluated over approximately one year of treatment.
Participants received apitegromab by intravenous infusion every four weeks.
The main efficacy population included children aged 2 to 12 years, while an exploratory group included participants aged 13 to 21 years.
What did the SAPPHIRE trial find?
SAPPHIRE successfully met its primary endpoint.
Motor function was measured using the Hammersmith Functional Motor Scale Expanded, commonly shortened to HFMSE.
This is a 33 item clinical assessment used to measure physical abilities in people with Type 2 and Type 3 SMA.
Participants receiving apitegromab experienced statistically significant improvement compared with placebo.
Nearly one third of apitegromab treated participants achieved at least a three point improvement in HFMSE.
The same level of improvement occurred in 12.5% of participants receiving placebo.
Scholar Rock reported improvement compared with placebo from the first measured time point.
What does a three point improvement mean?
The HFMSE measures real physical abilities rather than simply measuring muscle size.
Tasks assess abilities relevant to everyday movement and motor function.
This is particularly important because one of the longstanding questions surrounding myostatin inhibition has been whether increasing muscle translates into meaningful improvements in function.
Apitegromab moved the myostatin field beyond simply showing changes in muscle biomarkers or size. The Phase 3 trial demonstrated statistically significant and clinically meaningful improvement in a functional motor endpoint.
How significant were the results?
The Phase 3 results are important because previous attempts to develop myostatin inhibitors have often produced disappointing clinical outcomes.
Some experimental compounds successfully increased lean mass but failed to produce equally convincing improvements in strength or physical function.
Apitegromab appears to have crossed an important threshold.
Motor function improved
In the main SAPPHIRE efficacy population, apitegromab produced a statistically significant improvement in HFMSE compared with placebo.
Benefits were reported across major predefined subgroups, including age and background SMA therapy.
The results were subsequently published in The Lancet Neurology in 2025.
Apitegromab does not work like testosterone
Myostatin inhibitors are sometimes discussed as if they are simply a new generation of anabolic steroids.
That comparison is misleading.
| Feature | Apitegromab | Anabolic steroids |
|---|---|---|
| Primary target | Myostatin activation | Androgen receptor |
| Drug type | Monoclonal antibody | Steroid hormone derivative |
| Primary development | Neuromuscular disease | Various approved medical uses |
| Androgenic? | No | Yes |
| Healthy bodybuilding evidence? | Not established | Extensive non-medical history |
Apitegromab does not activate androgen receptors.
Instead, it attempts to remove one of the body’s natural restrictions on skeletal muscle.
Apitegromab vs trevogrumab
Apitegromab and trevogrumab both target the myostatin pathway, but they target different stages of it.
Binds pro and latent myostatin and prevents the production of active myostatin.
Binds myostatin itself and prevents the mature protein from producing its normal signalling effect.
| Feature | Apitegromab | Trevogrumab |
|---|---|---|
| Development code | SRK-015 | REGN1033 |
| Developer | Scholar Rock | Regeneron |
| Target | Pro & latent myostatin | Active myostatin / GDF-8 |
| Strategy | Prevent activation | Neutralise myostatin |
| Major current program | Spinal muscular atrophy | Obesity / lean mass preservation |
| Clinical stage | Phase 3 completed | Phase 2 obesity program |
What do we know about apitegromab safety?
Apitegromab has now accumulated considerably more human treatment experience than many experimental compounds discussed in the myostatin field.
Scholar Rock reported that the safety profile in SAPPHIRE was consistent with previous clinical experience from its earlier TOPAZ study.
Long term extension research has also allowed some SMA participants to receive apitegromab for multiple years.
However, this does not mean that safety has been established for healthy people or for non-medical muscle enhancement.
Is apitegromab approved?
As of August 2026, apitegromab remains an investigational medicine.
However, it is considerably closer to possible regulatory approval than most compounds in the myostatin field.
Scholar Rock submitted a Biologics License Application to the US Food and Drug Administration following the positive Phase 3 SAPPHIRE results.
The application has been accepted by the FDA.
Scholar Rock reported in May 2026 that the FDA had assigned a 30 September 2026 PDUFA action date.
This is the target date by which the FDA is expected to make a decision on the application.
A European Marketing Authorisation Application has also been under regulatory review.
Regulatory review does not guarantee approval. Until a regulator formally approves the medicine, apitegromab remains investigational.
Is apitegromab available in Australia?
Apitegromab should currently be considered an investigational pharmaceutical treatment rather than an established medicine routinely available in Australia.
Its advanced clinical development does not mean that products advertised online as apitegromab are equivalent to Scholar Rock’s pharmaceutical product.
This distinction is particularly important because monoclonal antibodies are complex biological medicines.
Manufacturing, purification, storage and quality control are substantially more complex than simply synthesising a short peptide.
The existence of an online listing labelled “apitegromab” or “SRK-015” does not establish identity, purity, biological activity or equivalence to the material used in Scholar Rock’s clinical trials.
Apitegromab research summary
| Question | Current position |
|---|---|
| What is it? | Fully human monoclonal antibody |
| Other name | SRK-015 |
| Developer | Scholar Rock |
| Target | Pro and latent myostatin |
| Mechanism | Prevents activation of mature myostatin |
| Drug type | IgG4 monoclonal antibody |
| Major indication | Spinal muscular atrophy |
| Phase 3 completed? | Yes |
| Phase 3 successful? | Yes, primary endpoint met |
| FDA approved? | Not as of August 2026 |
| Healthy bodybuilding evidence? | Not established |
Why apitegromab matters for myostatin research
Apitegromab may prove to be an important milestone for the entire myostatin field.
Scientists have known for decades that reducing myostatin can dramatically alter skeletal muscle in animals.
Translating that biology into useful human medicines has been much more difficult.
Many previous drugs affected muscle mass without producing convincing improvements in real world physical function.
Apitegromab has now produced a successful Phase 3 result using a functional motor endpoint.
That does not mean it has proven the bodybuilding claims surrounding myostatin inhibition.
It does mean the underlying pathway is increasingly moving from theoretical muscle biology toward clinically validated medicine.
Apitegromab provides some of the strongest human evidence so far that selective manipulation of the myostatin pathway can produce clinically meaningful effects on muscle function.
The bottom line
Apitegromab is one of the most advanced myostatin targeting drugs currently in development.
Rather than blocking activin receptors or directly neutralising mature myostatin, apitegromab selectively binds the pro and latent forms of myostatin and prevents their activation.
This gives the drug a highly targeted mechanism.
The most important evidence comes from the Phase 3 SAPPHIRE trial in people with spinal muscular atrophy.
The trial met its primary endpoint and demonstrated statistically significant improvement in motor function when apitegromab was added to existing SMA therapy.
Nearly one third of treated participants in the main efficacy population achieved at least a three point improvement on the HFMSE motor scale compared with 12.5% receiving placebo.
Those results have taken apitegromab into regulatory review.
What the evidence does not establish is that apitegromab will produce dramatic muscle growth in healthy adults without exercise.
That remains a very different question from the medical indication currently being studied.
Apitegromab is important because it provides advanced human evidence that selective myostatin inhibition can translate into meaningful improvements in muscle function. Whether the same approach eventually has applications beyond neuromuscular disease remains an open research question.
Frequently asked questions
What is apitegromab?
Apitegromab is an investigational fully human monoclonal antibody developed by Scholar Rock that selectively inhibits the activation of myostatin.
Is SRK-015 the same as apitegromab?
Yes. SRK-015 is the development code originally used for apitegromab.
Is apitegromab a myostatin inhibitor?
Yes. Apitegromab binds pro and latent forms of myostatin and prevents them from being converted into biologically active mature myostatin.
Is apitegromab a peptide?
No. Apitegromab is a fully human monoclonal antibody rather than a conventional research peptide.
Does apitegromab build muscle?
Apitegromab reduces myostatin activity and has demonstrated clinically meaningful improvements in motor function in people with spinal muscular atrophy. Dramatic muscle growth in healthy adults has not been established.
How is apitegromab given?
In the Phase 3 SAPPHIRE trial, apitegromab was administered by intravenous infusion every four weeks.
What did the SAPPHIRE trial find?
The Phase 3 SAPPHIRE trial met its primary endpoint. Apitegromab produced statistically significant and clinically meaningful improvement in motor function compared with placebo when added to existing SMA treatment.
Is apitegromab FDA approved?
As of August 2026, apitegromab remains under regulatory review. Scholar Rock reported an FDA target action date of 30 September 2026.
Is apitegromab available in Australia?
Apitegromab is not currently an established medicine routinely available to Australian consumers and should still be considered investigational.
Explore related research
Explore the science behind myostatin and the major experimental compounds targeting muscle growth.
View the research hub → Related compound TrevogrumabExplore Regeneron’s antibody targeting active myostatin and its obesity research.
Read the guide → Related pathway GaretosmabLearn how activin A blockade may amplify the effects of myostatin inhibition.
Read the guide →Research sources
- Crawford TO, Servais L, Mercuri E, et al. Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a Phase 3, double blind, randomised, placebo controlled trial. The Lancet Neurology. 2025.
- ClinicalTrials.gov. NCT05156320. Phase 3 SAPPHIRE study of apitegromab in patients with later onset spinal muscular atrophy.
- Scholar Rock. Phase 3 SAPPHIRE clinical trial results and apitegromab clinical development updates.
- Scholar Rock. Apitegromab regulatory and Biologics License Application updates. 2025 to 2026.